BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, ...
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay ...
Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks ...
Powering Precision Health 2022 Alzheimer’s podcast announced in recognition of Biomarker Factory launch “Researchers are exploring the utility of ultrasensitive plasma biomarkers for drug trial ...
Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...
Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional ...
Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results